Abstract: A system and method for operation of an autonomous vehicle (AV) yard truck is provided. A processor facilitates autonomous movement of the AV yard truck, and connection to and disconnection from trailers. A plurality of sensors are interconnected with the processor that sense terrain/objects and assist in automatically connecting/disconnecting trailers. A server, interconnected, wirelessly with the processor, that tracks movement of the truck around and determines locations for trailer connection and disconnection. A door station unlatches/opens rear doors of the trailer when adjacent thereto, securing them in an opened position via clamps, etc. The system computes a height of the trailer, and/or if landing gear of the trailer is on the ground and interoperates with the fifth wheel to change height, and whether docking is safe, allowing a user to take manual control, and optimum charge time(s). Reversing sensors/safety, automated chocking, and intermodal container organization are also provided.

Abstract: A system and method for operation of an autonomous vehicle (AV) yard truck is provided. A processor facilitates autonomous movement of the AV yard truck, and connection to and disconnection from trailers. A plurality of sensors are interconnected with the processor that sense terrain/objects and assist in automatically connecting/disconnecting trailers. A server, interconnected, wirelessly with the processor, that tracks movement of the truck around and determines locations for trailer connection and disconnection. A door station unlatches/opens rear doors of the trailer when adjacent thereto, securing them in an opened position via clamps, etc. The system computes a height of the trailer, and/or if landing gear of the trailer is on the ground and interoperates with the fifth wheel to change height, and whether docking is safe, allowing a user to take manual control, and optimum charge time(s). Reversing sensors/safety, automated chocking, and intermodal container organization are also provided.

Abstract: A method for authenticating an electronic client device for purposes of granting/denying access to a secure network is provided. The network device detects whether a client device requesting access to the secure network is a known client device on a list maintained by the network device or an unrecognized client device that is not on the list. If the client device is detected as being an unrecognized client device, the network device causes a message to be sent to a manager of the secure network. When a response is received, identification information of the unrecognized client device is automatically added to the list of known client devices by the network device. A network device is also provided.

Abstract: Provided herein are, inter alia, methods of treating cancer in patients who have certain biomarkers in their blood, including administering T cells containing the blood-based biomarkers to the patients and treating and identifying cancer patients having T cells which contain the blood-based biomarkers.

Abstract: A thermal cycler for DNA amplification and real-time detection comprises a sample block with a position for a sample tube containing fluorescent molecules; an LED light for excitation of the fluorescent molecules at a predetermined wavelength; a filter that passes light at the predetermined wavelength to allow excitation of the fluorescent molecules; and a housing for the sample block, the LED light, and the filter that allows visualization of the fluorescent signal. The device may utilize a smart phone with a camera or the naked eye to detect fluorescence.

Abstract: A method for authenticating an electronic client device for purposes of granting/denying access to a secure network is provided. The network device detects whether a client device requesting access to the secure network is a known client device on a list maintained by the network device or an unrecognized client device that is not on the list. If the client device is detected as being an unrecognized client device, the network device causes a message to be sent to a manager of the secure network. When a response is received, identification information of the unrecognized client device is automatically added to the list of known client devices by the network device. A network device is also provided.

Abstract: Methods, systems, and computer readable media may be operable to facilitate the capture of a segment of a media stream. A media segment may be captured from a media stream in response to a received media segment capture request. A media segment type may be determined from a default setting or from a received user command identifying the desired media segment type. Based on the determined media segment type, the captured media segment may be converted to a media format associated with the media segment type, and the converted media segment may be stored or output to an external sever or client device. Information associated with the media segment or media stream from which the media segment is captured may be retrieved from the media stream or user input and may be added to the converted media segment as metadata.

Abstract: Methods of detecting surface markers on T-cells from skin samples are provided. T-cells can be isolated from skin samples for example using single density centrifugation. The percentage of CD8+ cells being CTLA4+PD-1+ can be used to predict responsiveness to anti-PD-1 therapy.

Abstract: Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.

Abstract: The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF121 fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary tumors and inhibit metastatic spread and vascularization of metastases. The VEGF121 fusion protein also target osteoclast precursor cells in vivo and inhibits osteoclastogenesis.

Abstract: The 121-amino acid isoform of vascular endothelial growth factor (VEGF121) is linked by a flexible G4S tether to a cytotoxic molecule such as toxin gelonin or granzyme B and expressed as a soluble fusion protein. The VEGF121, fusion protein exhibits significant anti-tumor vascular-ablative effects that inhibit the growth of primary tumors and inhibit metastatic spread and vascularization of metastases. The VEGF121 fusion protein also target osteoclast precursor cells in vivo and inhibits osteoclastogenesis.

Abstract: This patent discloses the use of water-soluble substituted fullerenes as inhibitors of cell death. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 —X3 groups bonded to the fullerene core; (iii) from 1 to 6 —X4— groups bonded to the fullerene core; or (iv) from 1 to 6 dendrons bonded to the fullerene core.

Abstract: The present invention provides novel immunotoxins and methods of treating neoplastic diseases. These immunotoxins are comprised of a conjugation of an antigen binding region exhibiting binding specificity for the CD33 protein and a cell growth modulator. The immunotoxins of the present invention specifically and selectively kill tumor cells that are characterized by the expression of CD33 antigen. Thus, the novel immunotoxins would be useful in treating human leukemias, both acute and chronic, and other myelodysplastic syndromes.

Abstract: Activation of nuclear factor kB (NF-kB) is involved in a number of diseases such as viral and bacterial infections, and cell proliferative disorders such as cancer and autoimmune disease. In certain instances, constitutive NF-kB activity has also been liked to the resistance of certain cancers to chemo and radiation therapy. The instant invention concerns method of inhibiting NF-kB activity in target cell populations by deliver of a polypeptide inhibitor of NF-kB (IkB). Methods of the invention may be used to treat diseases such as infections, and cell proliferative disorders. Methods for sensitizing cells to apoptosis and cytotoxic therapies are also described.

Abstract: The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.

Abstract: The present invention concerns methods of reducing the antigenicity of a proteinaceous compound while maintaining the compounds biological activity, as well as proteinaceous compositions with biological activity but reduced antigenicity. These methods and compositions have significant benefits to a subject in need of such compounds and compositions. Also included are modified toxin compounds that are truncated and/or possess reduce antigenicity. Such designer toxins have therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins. Methods of treating cancer using these immunotoxins are provided.

Abstract: Methods of treating or preventing eye disease in a subject, involving administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide having a vascular endothelial targeting amino acid sequence and a cytotoxic amino acid sequence are disclosed. For example, the vascular endothelial targeting amino acid sequence may be a VEGF sequence, such as a VEGF121 sequence. Exemplary cytotoxic amino acid sequences include toxin sequences, such as gelonin, pro-apoptotic sequences, and anti-angiogenic sequences. The eye disease may be any eye disease, such as an eye disease associated with choroidal neovascularization, retinal neovascularization, iris neovascularization, or corneal neovascularization.

Abstract: The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.

Abstract: The present invention concerns chimeric cancer therapeutic molecules comprising a targeting moiety and an anti-cell proliferation moiety. The anti-cell proliferation moiety may comprise a cytotoxic agent or an apoptosis-inducing factor, in specific embodiments. In particular embodiments, the anti-cell proliferation mechanism of the chimeric molecules comprises apoptotic pathways. In additional embodiments, the chimeric molecules of the present invention provide sensitivity to chemotherapy in a cell that is resistant to the chemotherapy.

Abstract: This patent discloses the use of water-soluble substituted fullerenes as inhibitors of cell death. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 -X3 groups bonded to the fullerene core; (iii) from 1 to 6 -X4- groups bonded to the fullerene core; or (iv) from 1 to 6 dendrons bonded to the fullerene core.